You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumoniaSBC: Arrevus, Inc. Topic: NIAID
Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: AGILE SCIENCES, INC. Topic: NIAID
DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SIXONE SOLUTIONS, LLC Topic: NCI
DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: CytoInformatics LLC Topic: NIAMS
DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Zen-Bio, Inc. Topic: NCI
DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: DISCOVERYBIOMED, INC. Topic: NIDCD
Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: FOR-ROBIN, INC. Topic: NCI
DESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Allinaire Therapeutics, LLC Topic: NHLBI
Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Science Take-Out, LLC Topic: R
ABSTRACT This supplement project will expand on our current STTR Phase I project in which we partnered with University of Rochesterandapos;s Environmental Health Sciences Center to develop three Science Take-Out vaping education kits. Our vaping education kits involve students in using hands-on activities and real-life scenarios to investigate the harmful effects of chemicals used in e-cigarette f ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: HEART IMAGING TECHNOLOGIES, LLC Topic: NHLBI
DESCRIPTION (provided by applicant): Medical drugs and devices are regulated by the U.S. Food and Drug Administration (FDA) based on data from multicenter clinical trials. In 2010, U.S. spending on clinical trials was approximately 25 billion. Over the past decade the efficiency of clinical trials has been improved by electronic data capture (EDC) systems, whose use has increased from 38% to 61% ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health